BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report)’s share price was down 3.8% during trading on Tuesday. The stock traded as low as C$10.60 and last traded at C$10.60. 3,402 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Performance
The stock has a market cap of C$168.68 million and a P/E ratio of -28.19. The company has a quick ratio of 128.68, a current ratio of 129.63 and a debt-to-equity ratio of 0.05. The business has a 50 day moving average price of C$10.60 and a two-hundred day moving average price of C$10.60.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
